Full text
Earnings transcript
Read the complete earnings call transcript.
MOLN
MOLN
Molecular Partners AG
$3.88
-0.07
(-1.77%)
| Exchange: | NASDAQ |
| Market Cap: | 145.543M |
| Shares Outstanding: | 25.001M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Patrick Amstutz | |||||
| Full Time Employees: | 158 | |||||
| Address: |
| |||||
| Website: | https://www.molecularpartners.com |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm’s pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 7,038 | 4,970 | 0 |
| Gross Profit | -40,806 | -42,534 | 0 |
| EBITDA | -59,515 | -51,647 | -59,487 |
| Operating Income | -61,108 | -61,217 | -58,124 |
| Net Income | -61,984 | -54,043 | -61,651 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 198,352 | 158,528 | 102,107 |
| Total Liabilities | 21,923 | 16,891 | 21,773 |
| Total Stockholders Equity | 176,429 | 141,637 | 80,334 |
| Total Debt | 3,652 | 2,444 | 3,644 |
| Cash and Cash Equivalents | 67,309 | 63,874 | 82,653 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -59,005 | -59,248 | -51,257 |
| Capital Expenditure | -575 | -723 | -714 |
| Free Cash Flow | -59,813 | -59,971 | -51,971 |
| Net Income | -61,984 | -54,043 | -61,651 |
| Net Change in Cash | -20,637 | -3,435 | 18,779 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 179,948.702 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 179,948.702 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 179,948.702 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -49,385.740 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -49,385.740 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -49,385.740 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 3,780.426 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 3,780.426 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 3,780.426 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 326,771.266 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 326,771.266 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 326,771.266 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.100 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.100 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.100 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about MOLN valuation
Is Molecular Partners AG (MOLN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Molecular Partners AG (MOLN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is MOLN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MOLN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is MOLN’s P/E ratio?
You can see MOLN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for MOLN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is MOLN a good long-term investment?
Whether MOLN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
MOLN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.77
Trading Metrics:
| Open: | 3.82 | Previous Close: | 3.95 | |
| Day Low: | 3.67 | Day High: | 3.88 | |
| Year Low: | 3.41 | Year High: | 5.36 | |
| Price Avg 50: | 4.11 | Price Avg 200: | 4.16 | |
| Volume: | 2296 | Average Volume: | 4468 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeCould not create stock discussion for MOLN
